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Background:Recently, interferon-free treatment has been considered for the treatment
of chronic hepatitis C due to their high therapeutic success and lack of serious side
effects. The combination of Sofosbuvir and Daclatasvir is effective in the treatment
of the disease because of its pan-genotype. In the present study, the effectiveness
of Sovodak, which is a combination of the aforementioned two drugs in one tablet, in
the treatment of patients with chronic hepatitis C and cirrhosis was investigated.
Methods: Patients with chronic hepatitis C whose diagnosis was confirmed by HCV
RNA–PCR test were included in the study. These patients received one Sovodak tablet
daily (for 12 weeks for non-cirrhotic patients and 24 weeks for cirrhotic patients).
Sustained virologic response (SVR) was assessed by PCR test 12 weeks after the
end of the treatment and one year later. Also, serum levels of liver enzymes, platelet
count, and liver stiffness (using elastography method) were measured and their levels
were compared before and after treatment in patients.
Results: Findings related to the PCR test in patients showed that the level of SVR
was 100% in patients 12 weeks after treatment (SVR-12). In three cirrhotic patients
who received only 12 weeks of drug treatment, the disease recurred a year later.
According to the results, ALT and AST serum levels were significantly decreased
(P < 0.001), and platelet count level was increased (P < 0.001) one year after the end of
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the treatment period. Also, the liver stiffness index measured using FibroScan was
significantly decreased in patients 12 weeks after the end of the treatment (P < 0.001).
Conclusion: The results of this study, in line with other studies, showed the effective
role of Sovodak in completely eliminating the HCV virus in patients with chronic
hepatitis C. Cirrhotic patients need to receive treatment for at least six months.
Keywords: Sovodak, hepatitis C, sustained virologic response, effectiveness, liver
cirrhosis
1. Introduction
Chronic hepatitis is one of the most important health challenges in the world due to the
difficulty of its treatment. Chronic hepatitis C can lead to liver cirrhosis, hepatocellular
carcinoma, liver failure, and finally, death [1]. It is estimated that about 60–113 million
people worldwide are affected by this disease and the prevalence is increasing [2]. Its
prevalence in Iran is reported to be about 0.3–0.5% [3] and is expected to increase
further if the current conditions persist [4].
Hepatitis C virus (HCV) is a single-stranded RNA and enveloped virus belonging
to the Flaviviridae family and has six genotypes and a large number of subtypes [5–
8]. Treatment for chronic hepatitis C, before the development of direct-acting antiviral
(DAA) drugs, mainly involved the administration of pegylated interferon (IFN) Alfa with
Ribavirin. Treatment is successful when HCV RNA is undetected at the end of treatment
[9]. The side effects of interferon are sometimes so severe that the drug cannot be
used completely. Particularly in patients with cirrhosis, thrombocytopenia, and anemia,
it is often impossible to use this substance. Sometimes interferon aggravates the liver
disease and even death. The treatment period with interferon can last up to one and
a half years and includes weekly injections of the drug along with five to six tablets
of Ribavirin daily. With all of the above, even if the drug is fully used, the response to
treatment is about 60% or up to 70%, and many patients, such as those with cirrhosis
or HIV, respond less to the treatment [10].
With the introduction of DAA drugs, chronic hepatitis C can now be treated without
interferon and there is a lot of hope for effective treatment of this disease to the point
that some studies have even suggested the possibility of eradicating the disease as
the eradication of the first chronic viral disease in the world [11]. The approach of most
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therapies based on DAAs is Sofosbuvir, which alone is not effective and should be
used in combination with other medicines such as Daclatasvir or Ledipasvir. The most
familiar drug is Harvoni, a combination of Sofosbuvir and Ledipasvir in one tablet. This
drug is effective only on genotypes 1 and 4, which includes a maximum of 50–60% of
Iranian patients [12]. The combination of Daclatasvir and Sofosbuvir is effective on all
genotypes (pan-genotype) and can be used even without checking the genotype. The
combination of these two drugs in one tablet is only available in Iran, which is known
as Sovodak [13]. The present study investigated the effectiveness of Sovodak in the
treatment of patients with chronic hepatitis C and cirrhosis.
2. Materials and Methods
2.1. Study design
In this non-experimental study (before and after), all patients with chronic hepatitis C
referred to the outpatient clinic of the liver and gastrointestinal unit of Tohid Hospital,
Sanandaj, Iran in 2018, were selected by census method.
2.2. Patients
The inclusion criteria of the study comprised of patients aged between 20 and 80 years
and a confirmed diagnosis of the disease by HCV RNA–PCR test. Patients with renal
failure (eGFR < 30 ml/min), heart rate < 50, co-infection with HBV and HIV, and patients
taking amiodarone were excluded from the study.
2.3. Treatment and intervention methods
One Sovodak tablet (Sofosbuvir [400 mg] + Daclatasvir [60 mg] made in Rojan Pharma,
Tehran, Iran) was prescribed daily for all patients. Non-cirrhotic patients were treated for
12 weeks and patients with liver cirrhosis were treated for 24 weeks. The drugs were
given to patients monthly and were evaluated for side effects and proper use of the
drug.
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2.4. Paraclinical investigation
Serum levels of liver enzymes including alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were measured by kinetic method (Pars Azmoon Co., Tehran,
Iran). Platelet count was also measured at the beginning and 12 weeks after the end
of the treatment in all patients. All experiments were conducted in a laboratory. The
rate of hepatic fibrosis in the patients was assessed by the Transient Elastography
method using a FibroScan (EchoSens, Paris, France) at the beginning and one year
after the end of the treatment period. Fibrosis results were reported in kilopascal (Kpa).
Diagnosis of cirrhosis in patients was based on the results of FibroScan (F > 14 Kpa) and
the incidence of clinical manifestations including a set of clinical symptoms, physical
findings, laboratory, and radiological findings such as ascites, cytopenia, splenomegaly,
esophageal varices.
To evaluate the response to treatment, 12 weeks after the end of treatment and to
evaluate the recurrence, one year after the end of treatment, HCV RNA–PCR test was
performed with a diagnostic accuracy of 25 viral units per ml (copies/ml) of all patients.
2.5. Statistical analysis
Statistical analysis was performed using SPSS software version 20. The Kolmogorov–
Smirnov test was used to analyze the hypotheses for the normality of quantitative data.
Qualitative variables were calculated as frequency (percentage), quantitative variables
with normal mean distribution (SE), and qualitative variables with abnormal distribution
with mean (IQR). Due to the abnormality of data distribution, the Wilcoxon signed-rank
test was used to compare changes before and after the treatment of variables. P-value
< 0.05 was considered as a significant level.
3. Results
A total of 50 patients were enrolled in the study, and excluding 3, all 47 of them
completed the treatment period. The demographic and clinical characteristics of the
studied patients are summarized in Table 1. The mean age of patients was 49.30 ±
(10.71) years (with a minimum of 25 years and a maximum of 71 years). Overall, 42
patients (84%) were men and 8 (16%) were women. Most patients (32, 64%) were aged
between 40 and 60 years, 10 (20%) were under 40 years old, and only 8 people were
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over 60 years old. Pretreatment viral load in 25 patients (71.4%) was <600,000 IU/Ml
and in 10 patients (28.6%) ≥600,000 IU/Ml.
Seven patients (14%) were genotype 1, seven (14%) were genotype 3, and the genotype
of the remaining thirty-six patients (72%) was not determined. Based on the results of
FibroScan, 13 patients (26%) had cirrhosis of the liver. Findings related to the PCR test in
patients revealed that the level of sustained virologic response (SVR) 12 weeks after the
end of treatment in patients was 100%. Moreover, at one-year follow-up, recurrence was
not observed in 47 patients (94%). In three cirrhotic patients who were treated for only
three months due to non-referral to complete the second trimester of the treatment,
although the response to treatment was complete, the disease recurred after one year.
The patients were re-treated for 24 weeks, the response to treatment was complete
and a year later, no recurrence of the disease was observed in them.
Table 2 shows the level of liver enzymes and the platelet count before and 12 weeks
after the end of the treatment period in the studied patients. Based on the results,
serum ALT and AST levels in patients after treatment were decreased (P < 0.001), and
platelet count increased (P < 0.001) significantly. Also, the liver stiffness index measured
using FibroScan was decreased (P < 0.001) significantly in patients after the end of the
treatment period. One year after the end of treatment, patients had a median of 18%
reduction in liver stiffness index measured by FibroScan, from 6.95 (IQR; 5.15–15.00)
KPa to 5.70 (IQR; 3.57–14.40) Kpa (p < 0.001) compared to the data before Sovodak
administration.
TABLE 1: Baseline characteristics of the study patients (n = 50).
Variables
Age (yr), Mean ± (SD) 49.30 ± (10.71)
Sex, n (%) Male 42 (84.0%)
Female 8(16.0%)
Viral load, n (%) <600,000 IU/Ml 25 (71.4%)
≥600,000 IU/Ml 10 (28.6%)
Genotypes, n (%) 1 7 (50.0%)
2 0 (0%)
3 7 (50.0%)
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TABLE 2: Comparison of ALT, AST, platelet count, and liver stiffness index before and after treatment in
patients with chronic hepatitis C.
Variables Before treatment 12 weeks after completing
therapy
P-value
Med (IQR) Med (IQR)
ALT, U/L 42.00 (27.50–72.50) 27.50 (24.00–32.25) <0.001
AST, U/L 50.00 (30.75–70.50) 25.00 (22.00–28.00) <0.001





ALT: Alanine aminotransferase; AST: Aspartate aminotransferase
4. Discussion
The main findings of this study indicate that the administration of Sovodak for 12 and
24 weeks in non-cirrhotic and cirrhotic patients with chronic hepatitis C, respectively, is
completely effective in treatment, and that if the treatment is given to cirrhotic patients for
only 12 weeks, there is a possibility of recurrence of the disease despite the success of
SVR-12. In recent years, studies have been conducted on the effectiveness of Sovodak
or its family in the treatment of chronic hepatitis C. In the study of Mehdipour et al.
(2019), as in our study, the level of SVR12 in patients with HCV infection and genotype
1 treated with Sovodak was reported to be 100%. Although in this study, the duration
of treatment for cirrhotic patients was the same as for non-cirrhotic patients, that is,
12 weeks, Ribavirin was included in their treatment diet [14]. In another study on the
effectiveness of Sovodak on the treatment of 1,361 patients with hepatitis C and different
genotypes, the level of SVR-12 was reported to be 98%. In this study, the duration of
treatment in cirrhotic patients was 24 weeks and if Ribavirin was administered with
Sovodak, it was 12 weeks. There was no significant difference between the SVR12
levels in cirrhotic patients treated with Sovodak for 12 weeks with Ribavirin and 24
weeks without Ribavirin [15]. In other studies, the level of SVR-12 in the treatment of
patients with hepatitis C with Sofosbuvir and Daclatasvir has been reported to be 84.9–
100% [16–21]. Differences in SVR12 between several studies may be due to differences
in inclusion criteria (patients with cirrhosis or not), specific genotype, previous treatment
history, treatment failure, recurrence, multidrug usage, and use of other antiviral drugs
such as Ribavirin with Sofosbuvir/Daclatasvir.
Nelson et al. reported that in patients with HCV genotype 3, 12 weeks of treatment
with Sofosbuvir and Daclatasvir resulted in SVR-12 levels of up to 90% in patients
without cirrhosis and 86% in patients with cirrhosis [22]. In another study, Pol et al.
reported 96% and 88% of SVR12 in patients without cirrhosis and cirrhosis with HCV
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and genotype 1 treated with Sofosbuvir and Daclatasvir, respectively [16]. Merat et al.
(2017) in a study evaluated the effectiveness of treatment with Sovodak and Ribavirin
for 12 weeks in cirrhotic patients with hepatitis C and genotypes 1 and 3, in which the
SVR12 level was 98%. In two patients in which the recurrence occurred, one patient had
genotype 1 and other one had genotype 3 [23]. In the study of Leroy et al. (2016), SVR12
in cirrhotic patients with HCV genotype 3 infection with 12 and 16 weeks of treatment
with Sofosbuvir/Daclatasvir with Ribavirin were 83% and 89%, respectively [24]. In the
present research, it was shown that if cirrhotic patients were treated for 24 weeks, their
SVR12 was 100% and there was no recurrence of the disease at the one-year follow-
up. However, in three patients who continued treatment for only 12 weeks, although
they achieved SVR12, recurrence occurred a year later, with re-treatment for 24 weeks,
complete response to treatment, and no recurrence for up to a year.
In the present study, unlike the other aforementioned studies, the treatment period
in cirrhotic patients was 24 weeks and Ribavirin was not used. The results of the
present study showed that the rate of liver stiffness, measured by FibroScan, after
taking Sovodak in these patients decreased significantly. Sustained viral response (SVR)
is associated with cessation of disease progression and reduction of its complications,
including reduced incidence of hepatocellular carcinoma [25–27]. In previous studies,
liver tissue healing after an SVR has been reported [28–31] . The results of a study
revealed that treatment of chronic hepatitis C with DAA drugs in patients with cirrhosis
of the liver or advanced liver fibrosis is associated with cessation of cirrhosis and
regression of liver fibrosis in about 50% of patients [32].
Other findings of this study showed that taking Sovodak in patients with chronic
hepatitis C would significantly decrease the liver enzyme levels. This finding was in
agreement with the results of other studies that have been conducted in this field
[14, 19, 20] which indicates the effect of Sovodak on reducing liver enzymes levels to
normal, which could be due to the preventive effect of Sovodak on further destruction
of liver tissue by HCV and possibly liver tissue healing. Also in our study, platelet count,
in line with the effect of Sovodak in removing the virus, showed changes in recovery
so that cirrhotic patients had an increase in platelet count to normal range. The main
limitations of this study were the small number of sample and the lack of genotype of
all patients.
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5. Conclusion
The results of our study in line with other research, the effective role of Sovodak in
removing the HCV virus in patients with chronic hepatitis C was 100%. Therefore, this
drug is recommended due to the pan-genotype of the drug and its cheapness compared
to similar cases, without the need to determine the genotype and high cost of testing
and also the lack of significant drug side effects, for the treatment of all patients with
chronic hepatitis C in both cirrhotic and non-cirrhotic patients regardless of the type of
HCV genotype.
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